(NASDAQ: OPTN) Optinose's forecast annual revenue growth rate of 22.82% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.41%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.56%.
Optinose's revenue in 2023 is $71,979,000.On average, 2 Wall Street analysts forecast OPTN's revenue for 2023 to be $7,941,018,829, with the lowest OPTN revenue forecast at $7,907,886,793, and the highest OPTN revenue forecast at $7,974,150,864. On average, 2 Wall Street analysts forecast OPTN's revenue for 2024 to be $10,946,487,521, with the lowest OPTN revenue forecast at $9,370,188,825, and the highest OPTN revenue forecast at $12,522,786,216.
In 2025, OPTN is forecast to generate $15,183,457,117 in revenue, with the lowest revenue forecast at $11,588,350,509 and the highest revenue forecast at $18,778,563,725.